Logo Twitter Logo Youtube Publications

Clinical trials


Multi-modal neuroimaging in Alzheimer’s disease

IMAP / IMAP+ is a large observational trial aimed at improving our understanding of healthy and pathological ageing, sponsored by the University Hospital of Caen, France and funded by Fondation Plan Alzheimer (Alzheimer Plan 2008-2012), Programme Hospitalier de Recherche Clinique (PHRC National 2011 & 2012), Agence Nationale de la Recherche (ANR LONGVIE 2007), Région Basse Normandie, and Institut National de la Santé et de la Recherche Médicale (Inserm).

230 healthy individuals, aged 18 to 90 years and 165 patients with different degrees of cognitive impairment (from subjective cognitive decline, mild cognitive impairment, to Alzheimer’s disease and other dementia) were included in this study. They underwent detailed neuropsychological examination, sleep assessment (including actimetry and polysomnography), questionnaires assessing quality of life and lifestyle factors, blood sampling and complementary neuroimaging scans including structural and functional MRI and PET scans to measure glucose metabolism (FDG-PET) and β-amyloid deposition (florbetapir-PET). Participants were followed-up over 18 to 36 months with the same clinical, neuropsychological, sleep, questionnaires, blood sampling and neuroimaging examinations.

More than 80 articles have been published in peer-reviewed journals using the data collected in the IMAP/IMAP+ trial, and publications are still on-going. Among the different topics of interest studied: multimodal neuroimaging to better understand the physiopathological mechanisms of the disease, brain mechanisms underlying specific cognitive deficits, role of amyloid deposition over the course of the disease, influence of brain connectivity of brain lesion topography and spread, relationships between lifestyle factors or sleep quality and different neuroimaging biomarkers, brain changes over the course of Alzheimer’s disease, subjective cognitive decline, hippocampal subfields, new biomarkers for early diagnosis and innovative neuroimaging developments…